Payment overview · 2025
General Payments
$5,060.27
86 reported records · 22 companies
Healthcare provider profile · identity verified
David Jay Dickoff, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · YONKERS, NY · NPI 1548202484
Verified facts
What the public records show
CMS Open Payments records show David Jay Dickoff, M.D. received $5,060.27 in general payments during 2025 across 86 reported records.
Takeda Pharmaceuticals U.S.A., Inc. accounted for 53.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nuplazid, Nurtec Odt.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Botox by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Nuplazid by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Nurtec Odt by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GAMMAGARD LIQUID as an associated drug or biological on 29 records involving 8 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Gammagard Liquid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $2,689.90 | 53.2% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $563.23 | 11.1% | 23 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $272.65 | 5.4% | 8 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $221.99 | 4.4% | 8 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $200.58 | 4.0% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $198.76 | 3.9% | 5 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $115.78 | 2.3% | 4 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $114.23 | 2.3% | 4 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $97.92 | 1.9% | 4 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$88.11 | 1.7% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $85.19 | 1.7% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $81.54 | 1.6% | 3 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $57.46 | 1.1% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $49.72 | 1.0% | 2 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $36.84 | 0.7% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $34.57 | 0.7% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.28 | 0.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $27.63 | 0.6% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $27.61 | 0.6% | 1 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $25.57 | 0.5% | 1 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $23.38 | 0.5% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $19.33 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,528.50 | 1 |
| Food and Beverage | $2,495.37 | 84 |
| Travel and Lodging | $36.40 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $2,689.90 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $296.48 | 13 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $271.36 | 11 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $221.99 | 8 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $198.76 | 5 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $189.78 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $167.69 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $131.62 | 5 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $115.78 | 4 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $114.23 | 4 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $97.92 | 4 | 2025 |
Source payment records
|
|||||
| PERCEPT PC BRAINSENSE Normalized: percept pc brainsense |
Device | Medtronic, Inc. | $88.11 | 1 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $87.50 | 3 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $85.19 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $81.54 | 3 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $80.65 | 4 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $80.65 | 4 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $49.72 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $48.28 | 2 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $39.82 | 2 | 2025 |
Source payment records
|
|||||
| FIRDAPSE Normalized: firdapse |
Drug | CATALYST PHARMACEUTICALS, INC. | $36.84 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $34.57 | 1 | 2025 |
Source payment records
|
|||||
| HORIZANT Normalized: horizant |
Drug | Azurity Pharmaceuticals, Inc. | $28.28 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $27.63 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $27.61 | 1 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $25.57 | 1 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $23.38 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $19.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | GAMMAGARD LIQUID open payments reported associated product |
CMS Open Payments — General Payments 29 supporting records · 8 recipient NPIs · example record 1223786557 |
Gammagard Liquid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 811 | 301 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 494 | 147 |
| Donepezil Hcl | Donepezil Hcl | 273 | 83 |
| Quetiapine Fumarate | Quetiapine Fumarate | 201 | 72 |
| Bupropion Xl | Bupropion Hcl | 185 | 64 |
| Topiramate | Topiramate | 172 | 59 |
| Memantine Hcl | Memantine Hcl | 158 | 44 |
| Meloxicam | Meloxicam | 157 | 68 |
| Divalproex Sodium Er | Divalproex Sodium | 154 | 48 |
| Gabapentin | Gabapentin | 130 | 50 |
| Levetiracetam | Levetiracetam | 120 | 36 |
| Rizatriptan | Rizatriptan Benzoate | 92 | 26 |
| Nadolol | Nadolol | 83 | 33 |
| Propranolol Hcl Er | Propranolol Hcl | 73 | 19 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 67 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 14 |
| Nuplazid | Pimavanserin Tartrate | 51 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 50 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 48 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 46 | 16 |
| Pregabalin | Pregabalin | 46 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 43 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 42 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 41 | 15 |
| Lamotrigine | Lamotrigine | 35 | suppressed |
| Mirtazapine | Mirtazapine | 33 | 12 |
| Amlodipine Besylate | Amlodipine Besylate | 30 | 14 |
| Carbamazepine Er | Carbamazepine | 30 | suppressed |
| Botox | Onabotulinumtoxina | 29 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 25 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 24 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 23 | suppressed |
| Phenobarbital | Phenobarbital | 23 | suppressed |
| Carbamazepine | Carbamazepine | 22 | suppressed |
| Prednisone | Prednisone | 22 | suppressed |
| Gammaked | Immune Globul G/Gly/Iga Avg 46 | 20 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 20 | suppressed |
| Rytary | Carbidopa/Levodopa | 19 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 17 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 17 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 17 | suppressed |
| Etodolac Er | Etodolac | 15 | 13 |
| Neupro | Rotigotine | 14 | suppressed |
| Selegiline Hcl | Selegiline Hcl | 14 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Galantamine Er | Galantamine Hbr | 13 | suppressed |
| Kesimpta Pen | Ofatumumab | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Amantadine | Amantadine Hcl | 11 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $5,060.27 · 86 records | Takeda Pharmaceuticals U.S.A., Inc. | AMYVID, CAPLYTA, FIRDAPSE, Gamunex-C, HORIZANT, HYQVIA, Hizentra, INGREZZA, JOURNAVX, KESIMPTA, KISUNLA, Leqembi, NUPLAZID, NURTEC ODT, OCTAGAM IMMUNE GLOBULIN (HUMAN), Ocrevus Zunovo, PANZYGA, PERCEPT PC BRAINSENSE, QULIPTA, REXULTI, Rystiggo, Symbravo, UBRELVY, VRAYLAR, VYALEV, VYVGART HYTRULO, ZAVZPRET, ZEPOSIA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nuplazid play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error